Free Trial

Adlai Nortye (NASDAQ:ANL) Trading Down 7.3% - Time to Sell?

Adlai Nortye logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares fell 7.3% on Monday, trading as low as $12.61 and last at $13.7150 on volume of ~280,743 shares, about 53% below the stock's average daily volume.
  • Analyst coverage is mixed—two Buys and one Sell—with a MarketBeat consensus rating of "Hold" and a consensus target price of $21.50; recent notes include HC Wainwright raising its target to $20 and Leerink initiating at $23.
  • The stock trades well above its technicals (50-day MA $9.89, 200-day MA $5.19) and has meaningful institutional ownership (35.21%), with SmartHarvest slightly increasing its stake in Q1.
  • MarketBeat previews top five stocks to own in May.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report)'s stock price dropped 7.3% on Monday . The company traded as low as $12.61 and last traded at $13.7150. Approximately 280,743 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 602,798 shares. The stock had previously closed at $14.80.

Analysts Set New Price Targets

ANL has been the subject of a number of analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Adlai Nortye to a "hold" rating in a research report on Saturday, March 7th. Leerink Partners initiated coverage on shares of Adlai Nortye in a research report on Friday, March 20th. They issued an "outperform" rating and a $23.00 price objective for the company. Finally, HC Wainwright upped their price objective on shares of Adlai Nortye from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $21.50.

Check Out Our Latest Analysis on ANL

Adlai Nortye Stock Performance

The firm's 50-day moving average price is $9.89 and its 200 day moving average price is $5.19.

Hedge Funds Weigh In On Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. SmartHarvest Portfolios LLC boosted its holdings in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Free Report) by 8.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,367 shares of the company's stock after acquiring an additional 1,279 shares during the period. SmartHarvest Portfolios LLC's holdings in Adlai Nortye were worth $113,000 at the end of the most recent quarter. 35.21% of the stock is owned by institutional investors and hedge funds.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Adlai Nortye Right Now?

Before you consider Adlai Nortye, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.

While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines